Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Explore Activities by Jeremy S. Abramson

Title
Format
Credit Type
Credits
CCO’s Conference to Clinic Highlights ​From ASH 2024 Annual Meeting: Lymphomas

Content Format:

Video

Credit Type:

AAPA | ACPE | AMA | ANCC

Credits:

1.00
ASH 2024 Conference to Clinic: Lymphomas

Content Format:

Conference Coverage

Credit Type:

AAPA | ACPE | AMA | ANCC

Credits:

1.00
An Expert’s Guide to ASH 2024: Preview of the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Individualizing CLL Therapy: Second-Line Treatment and Beyond

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.75
Individualizing CLL Therapy: Second-Line Treatment and Beyond

Content Format:

Slideset

Credit Type:

--

Credits:

--
Individualizing CLL Therapy: Frontline Treatment

Content Format:

Slideset

Credit Type:

--

Credits:

--
Individualizing CLL Therapy: Frontline Treatment

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.75
Current Clinical Practice and NCCN Guidelines for CLL/SLL

Content Format:

Podcast Episodes

Credit Type:

AAPA | ACPE | AMA | ANCC

Credits:

0.50
The Importance of Individualizing CLL/SLL Therapy

Content Format:

Slideset

Credit Type:

--

Credits:

--
Evolving Therapeutic Options in Aggressive B-Cell Lymphomas: Expert Guidance for the Community Multidisciplinary Team

Content Format:

Slideset

Credit Type:

--

Credits:

--
FAQs: Fine-tuning Contemporary Treatment for Patients With CLL/SLL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Effective Management of Patients with Relapsed/Refractory CLL/SLL

Content Format:

Slideset

Credit Type:

--

Credits:

--
Community Care Team Workshops: New Frontline Strategies Challenge Longtime Standards in DLBCL

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

1.00
FAQs: Incorporating Novel and Emerging Treatment Combinations Into the Management of Aggressive B-Cell Lymphomas

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
New Treatment Strategies in Aggressive B-Cell Lymphomas: Advances, Application, and a Glimpse of the Future

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.50
Selection and Sequencing of Available, New, and Emerging Agents for Relapsed/Refractory DLBCL

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Community Care Team Workshops: New Frontline Strategies Challenge Longtime Standards in DLBCL

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Aggressive B-Cell Lymphomas: Clinical Application of New Advances in Community Practice

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Chronic Lymphocytic Leukemia: Applying the Latest Data in Community Practice

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

1.00
Answers to Frequently Asked Questions on State-of-the-Art Management of CLL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
ExpressPointsGuideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions

Content Format:

Slideset

Credit Type:

--

Credits:

--
Optimal Selection of Therapy for Treatment-Naive CLL

Content Format:

Slideset

Credit Type:

--

Credits:

--
Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Expanding Approved CAR T-Cell Therapy Treatment Options for Patients With Lymphoma

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Expert Selections From ASH 2020: Lymphomas/CLL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy: FAQ

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
ExpressPoints Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy

Content Format:

Slideset

Credit Type:

--

Credits:

--
Optimal Selection of Therapy for Treatment-Naive CLL

Content Format:

Slideset

Credit Type:

--

Credits:

--
Cases in CLL: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy

Content Format:

Multimedia

Credit Type:

AANP | ACPE | AMA

Credits:

0.25
Cases in CLL Slides: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Cases in CLL: Options for an Older Patient Requiring First-line Therapy

Content Format:

Multimedia

Credit Type:

AANP | ACPE | AMA

Credits:

0.25
Cases in CLL Slides: Options for an Older Patient Requiring First-line Therapy

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Leveraging BTK Inhibition Strategies in B-Cell Malignancies: Expert Perspectives to Guide Clinical Decisions

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Approaches to Individualized Treatment for Chronic Lymphocytic Leukemia: Expert Guidance on Sequencing Therapy, Novel Agents, and Their Combinations

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Current Treatment Algorithm for CLL and Clinical Trial Spotlight: A Resource for Clinicians

Content Format:

PDF

Credit Type:

--

Credits:

--
How I Manage Adverse Events Associated With BTK Inhibitors

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--